
(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on medical dermatology, have entered into a license agreement to develop bispecific antibodies for up to three undisclosed target pairs. Almirall … Read the full press release